Verrica Pharmaceuticals Inc (NASDAQ:VRCA) reported financial results for the fourth quarter and full year 2025 that showcased a significant acceleration in revenue growth alongside a dramatically improved cost structure. The company's performance exceeded analyst expectations on key metrics, contributing to positive investor sentiment in pre-market trading.
Earnings and Revenue Versus Estimates
The company's fourth-quarter results surpassed consensus estimates on both the top and bottom lines. Verrica reported total revenue of $5.1 million, which exceeded the analyst estimate of approximately $4.6 million. More notably, the company's adjusted net loss per share narrowed considerably.
- Reported Non-GAAP EPS: -$0.51
- Analyst Estimate for Non-GAAP EPS: -$0.81
- Reported Q4 Revenue: $5.1 million
- Analyst Estimate for Q4 Revenue: $4.6 million
This outperformance was driven by strong growth of the company's commercial product, YCANTH, and milestone payments from its partnership in Japan. For the full year 2025, total revenue surged to $35.6 million, a substantial increase from $7.6 million in the prior year.
Market Reaction and Price Action
The market's initial reaction to the earnings report has been positive. In pre-market trading following the release, Verrica's stock showed notable strength. This upward movement suggests investors are encouraged by the dual narrative of accelerating revenue growth and significantly reduced operating losses. The company's strategic execution, particularly the reduction of selling, general, and administrative expenses by over 40% year-over-year while nearly doubling product sales volume, appears to be resonating with the market.
Key Highlights from the Press Release
Beyond the headline financial figures, the press release outlined several transformative developments for Verrica in 2025 that underpin its future strategy:
- Commercial Growth and Efficiency: Net revenue for YCANTH grew 130% to $15.3 million for the full year. Crucially, the company achieved this growth while reducing SG&A expenses by over 40%, demonstrating a more focused and efficient commercial model.
- Strengthened Balance Sheet: A private placement in November 2025 allowed the company to fully repay all outstanding debt. Verrica now has no debt and believes its cash runway extends into the first quarter of 2027.
- Pipeline Advancements: The first patient was dosed in the Phase 3 program for YCANTH in common warts in December 2025. The company is also advancing VP-315, its oncolytic peptide for basal cell carcinoma, toward a Phase 3 program in 2026.
- International Expansion: Partner Torii Pharmaceutical launched YCANTH in Japan in February 2026. Furthermore, the company gained alignment with European regulators on a pathway to file for approval in the EU without additional Phase 3 studies.
Looking Ahead
While the press release did not provide specific quantitative financial guidance for 2026, management expressed optimism about growing YCANTH sales in the U.S., entering new international markets, and advancing its late-stage pipeline. Analysts currently estimate the company's revenue for the full year 2026 to be approximately $28.7 million. For the upcoming first quarter of 2026, the consensus estimates project revenue of $5.7 million and a non-GAAP EPS loss of $0.51.
For a detailed view of Verrica's historical earnings performance and future analyst projections, you can review the earnings history and future estimates.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
